{
  "source": "PA-Med-Nec-Entyvio-SC.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2332-3\nProgram Prior Authorization/Medical Necessity\nMedication *Entyvio® (vedolizumab)\n*This program applies to the subcutaneous formulation of vedolizumab\nP&T Approval Date 4/2024, 5/2024, 10/2024\nEffective Date 1/1/2025\n1. Background:\nEntyvio (vedolizumab) for subcutaneous use is an integrin receptor antagonist indicated in adults for\nthe treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).\n2. Coverage Criteriaa:\nA. Ulcerative Colitis\n1. Initial Authorization\na. Entyvio for subcutaneous use will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) One of the following:\n(a) Patient has been established on therapy with Entyvio under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nmoderately to severely active ulcerative colitis\n-OR-\n(b) Both of the following:\ni. Patient is currently on Entyvio for subcutaneous use therapy as documented by\nclaims history or submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a manufacturer sponsored\nprogram (e.g., sample card which can be redeemed at a pharmacy for a free\nsupply of medication) as a means to establish as a current user of Entyvio*\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\n(3) Patient is not receiving Entyvio for subcutaneous use in combination with another\ntargeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi\n(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the receipt ",
    " (ustekinumab), Xeljanz (tofacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\na manufacturer sponsored program shall be required to meet initial authorization criteria as if\npatient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Entyvio for subcutaneous use will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Entyvio for subcutaneous use therapy\n-AND-\n(2) Patient is not receiving Entyvio for subcutaneous use in combination with another\ntargeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi\n(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\nB. Crohn’s Disease\n1. Initial Authorization\na. Entyvio for subcutaneous use will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active Crohn’s disease\n-AND-\n(2) One of the following:\n(a) Patient has been established on therapy with Entyvio under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nmoderately to severely active Crohn’s disease\n-OR-\n(b) Both of the following:\n© 2024 UnitedHealthcare Services, Inc.\n2\ni. Patient is currently on Entyvio for subcutaneous use therapy as documented by\nclaims history or submission of medical records (Document date and duration of\ntherapy):\n-AND-\nii. Patient has not received a manufacturer supplied sample at no cost in the\nprescriber’s office, or any form of assistance from a manufacturer sponsored\nprogram (e.g., sample card which can be redeemed at a pharmacy for a free\nsupply of medication) as a means to establish as a current user of En",
    " or any form of assistance from a manufacturer sponsored\nprogram (e.g., sample card which can be redeemed at a pharmacy for a free\nsupply of medication) as a means to establish as a current user of Entyvio*\n-AND-\n(3) Patient is not receiving Entyvio for subcutaneous use in combination with another\ntargeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi\n(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]\n-AND-\n(4) Prescribed by or in consultation with a gastroenterologist\n* Patients requesting initial authorization who were established on therapy via the receipt of a\nmanufacturer supplied sample at no cost in the prescriber’s office or any form of assistance from\na manufacturer sponsored program shall be required to meet initial authorization criteria as if\npatient were new to therapy.\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Entyvio for subcutaneous use will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Entyvio for subcutaneous use therapy\n-AND-\n(2) Patient is not receiving Entyvio for subcutaneous use in combination with another\ntargeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Omvoh (mirikizumab-mrkz), Rinvoq (upadacitinib), Simponi\n(golimumab), Skyrizi (risankizumab), Stelara (ustekinumab), Xeljanz (tofacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2024 UnitedHealthcare Services, Inc.\n3\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of aut",
    "Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Entyvio [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; April 2024.\nProgram Prior Authorization/Medical Necessity – Entyvio (vedolizumab)\nChange Control\n4/2024 New program.\n5/2024 Added coverage criteria for Crohn’s disease. Updated background and\nreference.\n10/2024 Updated coverage criteria for ulcerative colitis and Crohn’s disease.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}